His doctors gave him 2 or 3 months. A new early-stage Toronto cancer treatment, invikafusp alfa (a first-in-class, bispecific, dual T cell agonistic antibody), has been a 'lifesaver' thestar.com/news/canada/his-… via @torontostar
Free link to this article: thestar.com/gift-redeem?t=4b…
This cancer drug is saving lives. It's also threatening to break Canadian health-care budgets thestar.com/news/investigati… via @torontostar #medicine #cancer #healthcare
Noboru Ishiyama retweeted
The challenge of whether or not to fund promising new drugs. It’s not enough for a treatment to work, it has to work well and provide value for money, by @picardonhealth theglobeandmail.com/opinion/… via @GlobeDebate
Noboru Ishiyama retweeted
Servier bags a Black Diamond in the rough. My quick take on today's $BDTX deal via @ApexOnco oncologypipeline.com/apexonc…
Noboru Ishiyama retweeted
AT LONG LAST… The essential #adherensjunction mechanosensitive protein alpha-catenin is required for #cytokinesis fidelity. We credential a previously defined (but poorly understood) abscission factor in this process, LZTS2. 🧵1/12 rupress.org/jcb/article-abst…
Noboru Ishiyama retweeted
In @JCellBiol, Wang, Yemelyanov et al. @GottardiLab @NorthwesternMed find that the force-sensitive cell-cell #adhesion component alpha-catenin is required for #cytokinesis fidelity through LZTS2. hubs.la/Q031WQmd0
@PMResearch_UHN @xtalmountain @gingraslab1
#CellDivision
Noboru Ishiyama retweeted
Wang, Yemelyanov et al. @GottardiLab @NorthwesternMed find that the force-sensitive cell-cell #adhesion component alpha-catenin is required for #cytokinesis fidelity through LZTS2. hubs.la/Q031WKcm0
@PMResearch_UHN @xtalmountain @gingraslab1
#CellDivision
Noboru Ishiyama retweeted
There is a new tool on BioIcons to turn any protein (in PDB format) into a 2D vector illustration in SVG format. You can upload any PDB file or import from PDB, AlphaFoldDB or ESMFoldDB. Feedback welcome :)
bioicons.com/pdb2vector/
Revolution, interrupted: Why AI has failed to live up to the hype in drug development /via @globeandmail theglobeandmail.com/business…
"A drug molecule needs to bind to a protein in order to treat disease, and finding a match is a ridiculously complicated problem, in part because proteins can assume different shapes and structures. ... AI is of little help."
How Jim Carrey helped Raptors icon DeMar DeRozan face depression thestar.com/sports/raptors/h… via @torontostar
Noboru Ishiyama retweeted
OPIG DPhil student @GemmaLGordon led work to build and analyse "PLAbDab-nano: a database of camelid and shark nanobodies from patents and the literature". Just released on bioRxiv and available as an OPIG webapp:
Preprint: biorxiv.org/content/10.1101/…
Webapp: opig.stats.ox.ac.uk/webapps/…
Noboru Ishiyama retweeted
🎉 New formula Coot 1.1.09 in Brewsci/bio for Linux and macOS!
ℹ️ Crystallographic Object-Oriented Toolkit
🍺 brew install brewsci/bio/coot
#Bioinformatics
Noboru Ishiyama retweeted
In 2018, I started my journey at @RommieAmaro's lab working on mesoscale simulations of influenza virus. After ~5 years in the making, I'm happy to share that the paper is now published in @ACSCentSci!
pubs.acs.org/doi/full/10.102…
Instead of a 🧵, I made a trailer 🎞️🎥! Sound ON 🔊
Here is how you can add protein structures from PyMOL as interactive 3D models in PowerPoint: 1) In PyMOL, export VRML2 file. 2) Convert file from VRML2 to glTF format in Blender. 3) Insert as 3D model in PowerPoint. That's it! For more info: youtu.be/0DOZ0jj289k
Noboru Ishiyama retweeted
New on BioRxiv: The essential adherens junction mechanosensitive component alpha-catenin is required for cytokinesis fidelity. We also credential a previously defined (but poorly understood) abscission factor in this process, LZTS2.
α-catenin mechanosensitivity as a route to cytokinesis failure through sequestration of LZTS2 biorxiv.org/cgi/content/shor… #biorxiv_cellbio
Noboru Ishiyama retweeted
New preprint publication on ElasticBLAST, a cloud native application that performs #BLAST searches for a few to millions of query sequences in the Cloud! ow.ly/nScr50Mjwpw













